Thursday, February 13, 2020, San Francisco, California, 6:45 PM – 8:30 PM

Addressing Current Questions and Controversies in the Management of Prostate Cancer

Location
San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Time
6:30 PM – 6:45 PM — Registration
6:45 PM – 8:30 PM — Educational Dinner Meeting

Meeting Room
Yerba Buena Ballroom, Salons 1-7 (Lower B2 Level)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
 
Faculty
Emmanuel S Antonarakis, MD
Professor of Oncology and Urology
Johns Hopkins University
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Andrew J Armstrong, MD, ScM
Professor of Medicine, Surgery, Pharmacology and Cancer Biology
Director of Research
Duke Cancer Institute Center for Prostate and Urologic Cancers
Divisions of Medical Oncology and Urology
Duke University
Durham, North Carolina

Karim Fizazi, MD, PhD
Department of Cancer Medicine
GETUG President
Institute Gustave-Roussy
Professor in Oncology
University of Paris Sud
Villejuif
Paris, France


Matthew R Smith, MD, PhD
Claire and John Bertucci Endowed Chair in Genitourinary Cancers
Professor of Medicine
Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


Not an official event of the 2020 Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by any of the cosponsoring organizations of the 2020 Genitourinary Cancers Symposium.

Event Schedule

6:30 PM – 6:45 PM — Registration
6:45 PM – 8:30 PM — Educational Dinner Meeting

MODULE 1: Integration of Antiandrogens into the Management of Nonmetastatic Castration-Resistant Prostate Cancer (CRPC)

  • Impact of disease-free interval, PSA level, PSA doubling time and other patient-specific factors on the decision to initiate androgen deprivation therapy (ADT) for individuals with PSA-only relapse after definitive treatment
  • Structural compositions, pharmacology, pharmacokinetics and pharmacodynamics of the next-generation antiandrogens apalutamide, darolutamide and enzalutamide
  • Design, eligibility criteria and key efficacy outcomes observed in the Phase III SPARTAN, ARAMIS and PROSPER trials evaluating apalutamide, darolutamide and enzalutamide, respectively, for patients with nonmetastatic CRPC
  • Spectrum and frequency of toxicities, including CNS-related adverse events, associated with the use of apalutamide, darolutamide and enzalutamide in the SPARTAN, ARAMIS and PROSPER trials; rates of treatment discontinuation observed in each
  • FDA approvals of apalutamide, darolutamide and enzalutamide for patients with nonmetastatic CRPC; patient selection and practical integration into current clinical algorithms

MODULE 2: Current Treatment of Metastatic Hormone-Sensitive PC (mHSPC)

  • Long-term efficacy and quality-of-life data associated with the use of docetaxel or abiraterone and prednisone in combination with ADT for men with mHSPC
  • Design, entry criteria and primary and secondary endpoints of the Phase III ARCHES and TITAN trials assessing enzalutamide or apalutamide in combination with ADT compared to ADT alone for patients with mHSPC; key efficacy and safety outcomes
  • FDA approval of enzalutamide and apalutamide for patients with mHSPC and optimal integration into current clinical practice
  • Results from the Phase III ENZAMET study of enzalutamide in combination with ADT versus other nonsteroidal antiandrogens (eg, bicalutamide, nilutamide or flutamide) with ADT for patients with mHSPC
  • Rationale for the inclusion of early docetaxel in ENZAMET; effect of earlier use of docetaxel on the efficacy and safety of enzalutamide
  • Relevant clinical, biologic and practical factors (eg, age, duration of therapy, extent and sites of metastases) guiding the selection of secondary hormonal therapy versus chemotherapy and vice versa for mHSPC

MODULE 3: Optimal Management of Metastatic CRPC (mCRPC)

  • Significance of the earlier use of chemotherapy and secondary hormonal therapy in the selection and sequencing of systemic treatment for mCRPC
  • Clinical and/or biologic factors affecting the sequence and selection of secondary hormonal therapy, immunotherapy and cytotoxic therapy for patients with mCRPC
  • Key efficacy and safety findings from the CARD study evaluating cabazitaxel versus alternative androgen receptor (AR)-targeted therapy (abiraterone or enzalutamide) for patients with mCRPC who had received docetaxel and experienced disease progression on a prior AR-targeted agent; implications for therapeutic sequencing in mCRPC
  • Published research information on androgen receptor splice variant 7 (AR-V7) as a biomarker to predict resistance to secondary hormonal therapy; current role of AR-V7 assessment in clinical decision-making
  • Patient selection for and optimal integration of radium-223 into current mCRPC treatment algorithms; current clinical role and ongoing evaluation of radium-223 in combination with other systemic therapies
  • Available data with and ongoing trials of immune checkpoint inhibitors for patients with mPC

MODULE 4: PARP Inhibition as a Therapeutic Strategy in mPC

  • Incidence of BRCA1/2 mutations and other DNA damage repair abnormalities (eg, ATM, PALB2) in patients with PC; rationale for and proposed mechanisms of antitumor activity of PARP inhibitors in mPC
  • Early clinical trial data with the use of olaparib, rucaparib and niraparib for patients with progressive mCRPC; FDA breakthrough therapy designations and ongoing investigation
  • Results from the Phase III PROfound trial evaluating olaparib versus enzalutamide or abiraterone for mCRPC after failure of prior hormonal therapy in patients with homologous recombination repair gene mutations; potential role of olaparib in clinical practice
  • Spectrum and frequency of toxicities observed with PARP inhibitors in PC
  • Biologic rationale for and published research data with PARP inhibitors combined with other systemic agents (eg, secondary hormonal therapy, immune checkpoint inhibitors)
  • Ongoing Phase III trials evaluating the role of PARP inhibitors in patients with mPC (TRITON3, MAGNITUDE, PROPEL, TALAPRO-2, et cetera)

Target Audience
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer (PC).

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Appraise recent data on diagnostic and therapeutic advances in PC, and integrate this information, as appropriate, into current clinical care.
  • Evaluate the published research database supporting the recent FDA approvals of secondary hormonal agents in the management of non-metastatic castration-resistant PC (CRPC), and apply this information in the discussion of nonresearch treatment options for these individuals.
  • Appraise the similarities and differences among commercially available next-generation antiandrogens in an effort to personalize therapeutic selection for individual patients.
  • Recognize the potential side effects associated with hormonal agents commonly employed in the management of PC, and develop strategies to prevent, mitigate and manage resultant toxicities.
  • Explore available data on the use of cytotoxic and secondary hormonal therapy in the setting of hormone-sensitive metastatic PC to effectively design treatment plans for appropriate individuals.
  • Apply evidence-based research findings in the determination of best-practice selection and sequencing of available local and systemic treatment modalities for patients with metastatic CRPC.
  • Describe the rationale for testing patients with metastatic PC for BRCA1/2 or other related mutations, and advise individuals found to harbor these genetic abnormalities about emerging Phase III data documenting the efficacy of PARP inhibition in appropriately selected individuals.
  • Recall the design of ongoing research studies evaluating other novel agents and strategies for PC, and counsel appropriate patients about availability and participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and Research To Practice. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement
Penn State College of Medicine designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
It is the policy of Research To Practice and Penn State College of Medicine to ensure balance, independence, objectivity and scientific rigor in all their educational programs. All faculty, planners and managers participating in this activity are required to disclose any relevant financial relationship(s) they (or spouse/partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months, and the opportunity to affect the content of CME about the products or services of the commercial interest. Research To Practice and Penn State College of Medicine will ensure that any conflicts of interest are resolved before the educational activity occurs. Financial disclosures will be provided in meeting course materials.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genomic Health Inc, Merck and Sanofi Genzyme.

San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600


Meeting Room
Yerba Buena Ballroom, Salons 1-7 (Lower B2 Level)

Directions
The San Francisco Marriott Marquis is located just 2 blocks (less than 0.2 miles) from the Moscone Convention Center, where the 2020 Genitourinary Cancers Symposium is taking place.

This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.